Brokerages Set Pfizer Inc. (NYSE:PFE) Target Price at $29.17

Shares of Pfizer Inc. (NYSE:PFE) have been assigned an average rating of “Hold” from the twenty-two analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation, five have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $28.55.

Several research analysts recently weighed in on the company. TD Cowen decreased their target price on Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a research note on Tuesday, April 22nd. HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research note on Monday, May 19th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. BMO Capital Markets decreased their target price on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Finally, Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company.

Institutional Investors Weigh In On Pfizer

Several hedge funds have recently bought and sold shares of PFE. Rialto Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the 4th quarter worth about $27,000. Gould Capital LLC raised its stake in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer during the 1st quarter worth about $27,000. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the 4th quarter worth about $28,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.5%

NYSE:PFE opened at $25.45 on Friday. Pfizer has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a market cap of $144.66 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 0.92 and a beta of 0.58. The business has a fifty day moving average of $23.67 and a 200-day moving average of $24.84. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the prior year, the business posted $0.82 earnings per share. The company’s revenue for the quarter was down 7.8% compared to the same quarter last year. Equities analysts predict that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.76%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.